Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.

Multi-EATs have the potential to increase potency, reduce toxicity, and overcome tumor heterogeneity without excessive cytokine release. Arming T cells with multiple BsAbs deserves further exploration to prevent or to treat cancer resistance.